Home

HARMONY

 

MDS-3: Differential outcomes of patients with MDS undergoing HSCT vs non-transplant strategies
MDS-4 Impact of pre-transplant cytoreductive treatment on high-risk MDS patients undergoing allo-HSCT
HARMONY Alliance Partners and Asssociated Members meet at the General Assembly 2023
HARMONY Alliance highlights of 2022
End of year message and HARMONY Alliance highlights of 2022
New results at the Annual Meeting of the American Society of Hematology
AML-7: The impact of gender on genetic aberrations and clinical outcomes in AML
AML-8: Clinical Meaning and Prognostic Implications of Non-Canonical Non-Type A NPM1 Mutations in Acute Myeloid Leukemia
AML-6: Unravelling the Clinical Impact of Co-mutations in NPM1mut AML
MDS-2: A retrospective study of patients with Myelodysplastic Syndrome
Inspiring HARMONY Alliance General Assembly 2021 - 6th edition HARMONY - 2nd edition HARMONY PLUS
CLL-2: Exploring the occurrence of other malignancies in CLL patients using the HARMONY BigData platform
ALL: Delphi Survey Project: Towards a Core Outcome Set for Acute Lymphoblastic Leukemia (ALL)
PRESS RELEASE: New HARMONY CML Research Project will study the role of genetic aberrations in the disease course of Chronic Myeloid Leukemia.
PRESS RELEASE: HARMONY presents new insights in Chronic Lymphocytic Leukemia at EHA2021
Connect with us at the EHA2021 Virtual Congress and learn about new HARMONY results
#Bigdataforbloodcancer Blog: Selecting the right treatment for the right patient: The HARMONY approach.
#Bigdataforbloodcancer Blog: The HARMONY Alliance - a balance between Big Data and Cybersecurity, with a real impact on patients with Hematological tumors
CLL: Delphi Survey Project: Towards a Core Outcome Set for Chronic Lymphocytic Leukemia
MM-2: Contextualizing clinical trials by developing robust historical control arm cohort
AML-5: Exploring a role for HARMONY data as historical control in elderly Acute Myeloid Leukemia patients.
AML-4: Using big data to confirm the link between MRD and survival in AML
AML-3: Using big data to shed light on the clinical impact of genomic alterations in sAML/tAML
ALL-5: Exploring the prognostic significance of minimal residual disease (MRD) in children with ALL
1-24   25-48